Malignant Uterine Corpus Neoplasm — Trials

Malignant Uterine Corpus Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,571 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 411
Recruiting: 226
Ph III recruiting: 25
Growth YoY: +3.1%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 27.6%
Trials / 1,000 deaths: 50.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 1–50 of 475 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05112601	Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma	recruiting	Phase 2	81	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT05564377	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	recruiting	Phase 2	2,900	National Cancer Institute (NCI)NIH	2	Sep 28, 2026